Article
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
Arthritis research & therapy - 1 Jan 2006
Johansson Martin, Arlestig Lisbeth, Hallmans Göran, Rantapää-Dahlqvist Solbritt
Abstract excerpt
We analysed relationships between the PTPN22 1858 polymorphism and antibodies to cyclic citrullinated peptide (CCP), rheumatoid factors (RFs) and the shared epitope (SE) gene (HLA-DRB1*0404 or 0401) and determined their combined predictive value for rheumatoid arthritis (RA) in individuals who subsequently developed RA. This case-control study was nested within the Medical Biobank of Northern Sweden. Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
